Real-world Danish registry data show that biologic drug survival in psoriasis differs between biologic-naive and ...

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Discover how diet impacts psoriasis. Learn about anti-inflammatory foods like those in the Mediterranean diet and their role ...

Continued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 millionAdvancement of ZORYVE ...

Foresite Labs, LLC and Foresite Labs Affiliates 2021, LLC, both identified as ten percent owners of Alumis Inc (NASDAQ:ALMS), have purchased a total of 411,764 shares of common stock in Alumis on ...

ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...

The first purchase involved 117,647 shares, while the second purchase consisted of 294,117 shares.

American Skin Association (ASA) is pleased to announce that Steven A. Rosenberg, MD, PhD, a pioneering figure in cancer immunotherapy, was appointed as the newest member of its distinguished Board of ...

Topline data were announced from a phase 3b trial evaluating the concomitant use of ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.

I initially booked what The Spa at Cedarbrook Lodge calls the “Natural Dry Brush With Hot Towels” — a 30-minute treatment ...

Schrödinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to focus on advancing its ...